INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE STOCK EXCHANGES (AS DEFINED IN THE PROSPECTUS) IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA. (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (**"SEBI ICDR REGULATIONS"**)

IKS® HEALTH

Quality Practice. Quality Care.

(Please scan this QR code to view the Prospectus)

INVENTURUS KNOWLEDGE SOLUTIONS LIMITED

Our Company was incorporated as "Inventurus Knowledge Solutions Private Limited" under the Companies Act, 1956 at Goa, pursuant to a certificate of incorporation dated September 5, 2006, issued by the Registrar of Companies, Goa, Daman and Diu at Goa. The registered office of our Company was shifted from Panduronga Timblo Industries, Akash Bhavan, 2nd Floor, Opp. Canara Bank, Panjim, Goa, India to Building No. 5 & 6, Unit No. 801, 8th Floor, Mindspace SEZ, Thane Belapur Road, Airoli, Navi Mumbai, Thane, Maharashtra, India – 400 708, with effect from January 1, 2020. On the conversion of our Company to a public limited company, pursuant to a resolution passed by Board on October 14, 2022 and our Shareholders on October 17, 2022, the name of our Company was changed to "Inventurus Knowledge Solutions Limited", consequent to which a fresh certificate of incorporation dated November 4, 2022 was issued by the Registrar of Companies, Maharashtra at Mumbai ("**RoC**"). For details of change in name and the registered office, see "*History and Certain Corporate Matters – Brief History of our Company*" and "*History and Certain Corporate Matters – Changes in the Registered Office*" on page 246 of the Prospectus.

Registered and Corporate Office: Building No. 5 & 6, Unit No. 801, 8th Floor, Mindspace SEZ, Thane Belapur Road, Airoli, Navi Mumbai, Thane, Maharashtra – 400 708, India; Tel: +91 22 3964 3205

Contact Person: Sameer Chavan, Company Secretary and Compliance Officer; Tel: +91 22-3964 3205, **E-mail**: company.secretary@ikshealth.com; **Website**: https://www.ikshealth.com; **Corporate Identity Number**: U72200MH2006PLC337651

OUR PROMOTERS: SACHIN GUPTA, REKHA JHUNJHUNWALA, ARYAMAN JHUNJHUNWALA DISCRETIONARY TRUST, ARYAVIR JHUNJHUNWALA DISCRETIONARY TRUST AND NISHTHA JHUNJHUNWALA DISCRETIONARY TRUST

Our Company has filed the Prospectus dated December 16, 2024 with the RoC, and the Equity Shares are proposed to be listed on the National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") and the trading will commence on Thursday, December 19, 2024.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 18,795,510 EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF INVENTURUS KNOWLEDGE SOLUTIONS LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 1,329 PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 1,328) ("OFFER PRICE") AGGREGATING TO ₹ 24,979.23 MILLION, THROUGH AN OFFER FOR SALE OF 18,795,510 EQUITY SHARES OF FACE VALUE ₹ 1 AGGREGATING TO ₹ 24,979.23 MILLION, COMPRISING 1,119,300 EQUITY SHARES OF FACE VALUE ₹ 1 BY ARYAMAN JHUNJHUNWALA DISCRETIONARY TRUST AGGREGATING TO ₹ 1,487.55 MILLION, 1,119,300 EQUITY SHARES OF FACE VALUE ₹ 1 BY ARYAVIR JHUNJHUNWALA DISCRETIONARY TRUST AGGREGATING TO ₹ 1,487.55 MILLION, 1,119,300 EQUITY SHARES OF FACE VALUE ₹ 1 BY NISHTHA JHUNJHUNWALA DISCRETIONARY TRUST AGGREGATING TO ₹ 1,487.55 MILLION ("PROMOTER SELLING SHAREHOLDERS"), 3,376,311 EQUITY SHARES OF FACE VALUE ₹ 1 BY ASHRA FAMILY TRUST AGGREGATING TO ₹ 4,487.12 MILLION, 26,513 EQUITY SHARES OF FACE VALUE ₹ 1 BY RAJESHKUMAR RADHESHYAM JHUNJHUNWALA AGGREGATING TO ₹ 35.24 MILLION, ("PROMOTER GROUP SELLING SHAREHOLDERS"), 98,250 EQUITY SHARES OF FACE VALUE ₹ 1 BY ADHEET SHARAD GOGATE AGGREGATING TO ₹ 130.57 MILLION, 139,042 EQUITY SHARES OF FACE VALUE ₹ 1 BY AJAY MADHAVAN MADATIPARAMBIL AGGREGATING TO ₹ 184.79 MILLION, 72,051 EQUITY SHARES OF FACE VALUE ₹ 1 BY AJIT RAJAGOPAL MENON AGGREGATING TO ₹ 95.76 MILLION, 104,281 EQUITY SHARES OF FACE VALUE ₹ 1 BY ALAN MUNEY AGGREGATING TO ₹ 138.59 MILLION, 69,521 EQUITY SHARES OF FACE VALUE ₹ 1 BY ANKUR CHUGH AGGREGATING TO ₹ 92.39 MILLION, 323,572 EQUITY SHARES OF FACE VALUE ₹ 1 BY ANURAG SHIAMSUNDERLAL SHARMA AGGREGATING TO ₹ 430.03 MILLION, 49,126 EQUITY SHARES OF FACE VALUE ₹ 1 BY ARINDRAJIT DATTA AGGREGATING TO ₹ 65.29 MILLION, 83,425 EQUITY SHARES OF FACE VALUE ₹ 1 BY ASHIT KALRA AGGREGATING TO ₹ 110.87 MILLION, 676,549 EQUITY SHARES OF FACE VALUE ₹ 1 BY BERJIS MINOO DESAI AGGREGATING TO ₹ 899.13 MILLION, 5,297 EQUITY SHARES OF FACE VALUE ₹1 BY CHARLES EDWARD BROWN AGGREGATING TO ₹ 7.04 MILLION, 101,799 EQUITY SHARES OF FACE VALUE ₹ 1 BY CHRISTOPHER J SCLAFANI AGGREGATING TO ₹ 135.29 MILLION, 47,035 EQUITY SHARES OF FACE VALUE ₹1 BY CLARENCE CARLETON KING II AGGREGATING TO ₹ 62.51 MILLION, 33,406 EQUITY SHARES OF FACE VALUE ₹ 1 BY GAURAV JAIN AGGREGATING TO ₹ 44.40 MILLION, 1,251,378 EQUITY SHARES OF FACE VALUE ₹ 1 BY GAUTAM CHAR AGGREGATING TO ₹ 1,663.08 MILLION, 1,141,001 EQUITY SHARES OF FACE VALUE ₹ 1 BY JEFFREY PHILIP FREIMARK AGGREGATING TO ₹ 1,516.39 MILLION, 86,901 EQUITY SHARES OF FACE VALUE ₹ 1 BY JOHN BENARDELLO AGGREGATING TO ₹ 115.49 MILLION, 3,041,812 EQUITY SHARES OF FACE VALUE ₹1 BY JOSEPH BENARDELLO AGGREGATING TO ₹ 4,042.57 MILLION, 232,341 EQUITY SHARES OF FACE VALUE ₹ 1 BY K C NISHIL KUMAR AGGREGATING TO ₹ 308.78 MILLION, 49,126 EQUITY SHARES OF FACE VALUE ₹ 1 BY KAREEN RIBEIRO MAJMUDAR AGGREGATING TO ₹ 65.29 MILLION, 266,781 EQUITY SHARES OF FACE VALUE ₹ 1 BY KATHERINE NICOLE DAVIS AGGREGATING TO ₹ 354.55 MILLION, 130,594 EQUITY SHARES OF FACE VALUE ₹ 1 BY MADATHIPARAMBIL KRISHNAN MADHAVAN AGGREGATING TO ₹ 173.56 MILLION, 55,617 EQUITY SHARES OF FACE VALUE ₹ 1 BY MANISH GUPTA AGGREGATING TO ₹ 354.55 MILLION, 166,850 EQUITY SHARES OF FACE VALUE ₹ 1 BY MANU MAHMUD PARPIA (JOINTLY HELD WITH LYNN MANU PARPIA) AGGREGATING TO ₹ 221.74 MILLION, 61,290 EQUITY SHARES OF FACE VALUE ₹1 BY MAYUR PRAVINKANT SANGHVI AGGREGATING TO ₹ 81.45 MILLION, 219,170 EQUITY SHARES OF FACE VALUE ₹ 1 BY MITUL DIPAK THAKKER AGGREGATING TO ₹ 291.28 MILLION, 3,000 EQUITY SHARES OF FACE VALUE ₹ 1 BY NIKHIL SHARMA AGGREGATING TO ₹ 3.99 MILLION, 1,251,378 EQUITY SHARES OF FACE VALUE ₹ 1 BY PARMINDER BOLINA AGGREGATING TO ₹ 1,663.08 MILLION, 257,873 EQUITY SHARES OF FACE VALUE ₹ 1 BY PATRICK BURTON CLINE AGGREGATING TO ₹ 342.71 MILLION, 47,815 EQUITY SHARES OF FACE VALUE ₹ 1 BY SANJIV BHUPENDRA GANDHI AGGREGATING TO ₹ 63.55 MILLION, 652,008 EQUITY SHARES OF FACE VALUE ₹ 1 BY SCOTT D HAYWORTH AGGREGATING TO ₹ 866.52 MILLION, 994,233 EQUITY SHARES OF FACE VALUE ₹ 1 BY SHANE HSUING PENG AGGREGATING TO ₹ 1,321.34 MILLION, 15,000 EQUITY SHARES OF FACE VALUE ₹ 1 BY SRIKANTH VADAKAPURAPU AGGREGATING TO ₹ 19.94 MILLION, 208,563 EQUITY SHARES OF FACE VALUE ₹ 1 BY UNNIKRISHNAN PARTHASARATHY AGGREGATING TO ₹ 277.18 MILLION, 34,760 EQUITY SHARES OF FACE VALUE ₹ 1 BY VARADHARAJAN RAMASAMY AGGREGATING TO ₹ 46.20 MILLION AND 63,941 EQUITY SHARES OF FACE VALUE ₹ 1 BY VIKRAM JIT SINGH CHHATWAL AGGREGATING TO ₹ 84.98 MILLION, (THE "INDIVIDUAL SELLING SHAREHOLDERS", TOGETHER WITH THE PROMOTER SELLING SHAREHOLDERS AND PROMOTER GROUP SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS") (THE "OFFER FOR SALE" OR THE "OFFER"). THE OFFER INCLUDED A RESERVATION OF 65,000 EQUITY SHARES OF FACE VALUE ₹ 1 EACH, AGGREGATING TO ₹86.39 MILLION, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES NOT EXCEEDING 5% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER CONSTITUTED 10.95% AND 10.92%, RESPECTIVELY, OF THE FULLY DILUTED POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ANCHOR INVESTOR OFFER PRICE: ₹1,329 PER EQUITY SHARE OF FACE VALUE OF ₹ 1 EACH
OFFER PRICE: ₹ 1,329 PER EQUITY SHARE OF FACE VALUE OF ₹ 1 EACH
THE OFFER PRICE IS 1,329 TIMES THE FACE VALUE OF THE EQUITY SHARES.

RISKS TO INVESTORS

(For details refer to section titled "Risk Factors" on page 31 of the Prospectus)

1. **Concentration Risk**: Our revenues are concentrated from the US and below are the details regarding our revenues earned from the various geographies in the corresponding Fiscals / periods.

Country	Sept. 30, 2024	Sept. 30, 2023	2024	2023	2022
	Amount (₹ million)				
US[(1)]	12,286.92	6,308.71	17,783.18	10,313.00	7,636.34
India	-	-	0.00	-	-
Australia	234.67	-	111.41	-	-
Canada	307.17	-	272.97	-	-
UK	-	-	11.72	-	-
Total	**12,828.76**	**6,308.71**	**18,179.28**	**10,313.00**	**7,636.34**

(1) *Certain revenue generated in United Kingdom is billed and collected from a client based out of the US. However, the service is provided to an affiliate entity in the United Kingdom. Hence, there are no direct clients that are based out of the United Kingdom. However, a small portion of the revenue is generated from services provided in the United Kingdom.*

2. **Geographical Risk:** We are exposed to foreign currency exchange rate fluctuations, which may impact our results of operations, impact our cash flows and cause our financial results to fluctuate.
3. **Operating Risk:** Our revenues are dependent on our ability to maintain and expand existing client relationships and our ability to attract new clients in the US, Canada and Australia. In Fiscal 2024, we witnessed an increase in the number of clients primarily on account of our acquisition of Aquity (US).

Region	September 30, 2024	FY 2024
US	765	836
Australia	1	1
Canada	12	16

4. **Offer related Risk:** This Offer is 100% offer for sale and our Company will not directly receive any proceeds from the Offer and all the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer.
5. **Operational Risk:** Our success depends, in part, upon our ability to develop, innovate and introduce new solutions and add features to existing solutions. In the last three Fiscals and six months ended September 30, 2024, we have introduced a number of solutions including, IKS Scribble Pro, IKS Swift, Discharge Summary and Inbox Management. If we fail to successfully develop and introduce new solutions our revenues, operating results and reputation could suffer.
6. **Concentration Risk:** Various challenges are faced by the healthcare industry in the US including the provision of quality healthcare in a competitive environment, managing costs and consolidation of healthcare organizations which may adversely affect our business operating results and reputation could suffer.
7. **Financial Risk:** Delays in receiving payment of outstanding dues from clients may affect our financial condition and results of operations. The primary collection risk of our trade receivables relates to the failure by clients to pay in a timely manner and in full. Our contracts have a typical credit period of 30 days to 45 days and 90 days in exceptional cases. Our trade receivables turnover ratios for period ended September 30, 2024 and as at FY24' was 54.48 days and 52.82 days respectively.
8. **Regulatory Risk:** We operate in the highly regulated healthcare industry. In the U.S., we are required to comply with certain federal and state laws, regulations, and guidance. U.S. federal, and state governments, their respective agencies, and/or commercial health insurers may prohibit, or otherwise impose restrictions on, health care providers engaging companies. Some have already enacted such prohibitions or restrictions. We are also subject to laws and regulations governing relationships with our employees.
9. **Compliance Risk:** There have been FEMA related deficiencies in compliances in the past by our Company and some of our existing and erstwhile shareholders, with respect to issuance of securities of our Company, delays in relation to reporting requirements and transfer of securities of our Company. Company and Shareholders have filed 3 compounding applications each with RBI in respect of such contraventions, which are currently pending. Consequently, we may be subject to regulatory actions and penalties/ compounding fees, as applicable.
10. **Litigation Risk:** There are outstanding legal proceedings involving our Company and its subsidiaries (including 5 cases involving actions by statutory or regulatory authorities) amounting to ₹ 0.23 million and ₹ 249.42 million respectively. Such proceedings are pending at different levels of adjudication before various courts, tribunals and other authorities. an adverse outcome of which may adversely affect our business and reputation.
11. The details of weighted average cost of acquisition of all shares transacted by the Promoters, members of the Promoter Group, Selling Shareholders and shareholders with special rights in the last one year, eighteen months, and three years preceding the date of the Prospectus is as follows:

Period	Weighted Average Cost of Acquisition (in ₹)*	Cap Price is 'X' times the Weighted Average Cost of Acquisition*	Range of acquisition price: Lowest Price – Highest Price (in ₹)*
Last one year	696.17	1.91	75 – 771.00
Last eighteen months	64.26	20.68	3.92 – 771.00
Last three years	22.05	60.26	Nil – 771.00

* As certified by R T Jain and Co LLP, Chartered Accountants, by way of their certificate dated December 16, 2024.

12. The five Merchant Bankers associated with the Offer have handled 86 public issues in the past three years out of which 22 issues closed below the issue price on listing date.

Name of the Book Running Lead Managers ("BRLMs")	Total Public Issues	Issues closed below Offer Price on listing date
ICICI Securities Limited*	26	6
Jefferies India Private Limited*	1	0
JM Financial Limited*	20	5
J.P. Morgan India Private Limited*	2	2
Nomura Financial Advisory and Securities (India) Private Limited*	0	0
Common issues of above BRLMs	38	10
Total	**87**	**23**

* *Issues handled where there are no common BRLMs.*

Continued on next page.

...continued from previous page.

BID/OFFER PROGRAMME:
ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: WEDNESDAY, DECEMBER 11, 2024
BID/OFFER OPENED ON : THURSDAY, DECEMBER 12, 2024
BID/OFFER CLOSED ON : MONDAY, DECEMBER 16, 2024

The Offer was made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "**SCRR**"), read with Regulation 31 of the SEBI ICDR Regulations. The Offer was made through the Book Building Process in accordance with Regulation 6(2) of the SEBI ICDR Regulations wherein not less than 75% of the Net Offer was made available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**") (the "**QIB Portion**"), provided that our Company, in consultation with the BRLMs, allocated 60% of the QIB Portion to Anchor Investors and the basis of such allocation was on a discretionary basis by the Company, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations (the "**Anchor Investor Portion**"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids having been received from the domestic Mutual Funds at or above the price at which allocation was made to Anchor Investors ("**Anchor Investor Allocation Price**"). Further, 5% of the QIB Portion (excluding the Anchor Investor Portion) was made available for allocation on a proportionate basis only to Mutual Funds, subject to valid Bids having been received at or above the Offer Price, and the remainder of the QIB Portion was made available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. Further, not more than 15% of the Net Offer was made available for allocation to Non-Institutional Investors ("**Non-Institutional Category**") of which one-third of the Non-Institutional Category was made available for allocation to Bidders with an application size between ₹ 0.20 million to ₹ 1.00 million and two-thirds of the Non-Institutional Category was made available for allocation to Bidders with an application size of more than ₹ 1.00 million and under-subscription in either of these two sub-categories of Non-Institutional Category may have been allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received at or above the Offer Price. Further, not more than 10% of the Net Offer was made available for allocation to Retail Individual Investors ("**Retail Category**"), in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received from them at or above the Offer Price. Further, Equity Shares was allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids having been received from them at or above the Offer Price. All Bidders (except Anchor Investors) were required to mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("**ASBA**") process and to provide details of their respective bank account (including UPI ID for UPI Bidders using UPI Mechanism) in which the Bid Amount was blocked by the Self Certified Syndicate Banks ("**SCSBs**") or the Sponsor Bank, as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see "*Offer Procedure*" on page 540 of the Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, December 11, 2024. The company received a total of 61 applications from 47 anchor investors for 89,58,180 equity shares. The Anchor investor price was finalized at ₹ 1,329 per Equity Share. A total of 84,28,730 shares were allocated under the Anchor Investor Portion aggregating to ₹ 11,20,17,82,170.00

The Offer received 23,19,339 applications for 54,60,42,872 Equity Shares (after Anchor allocation and prior to rejection) resulting in 52.77 times subscription. The details of the applications received in the Offer from Retail Individual Bidders, Non-Institutional Bidders, Eligible Employees and QIBs are as under: (before rejections):

Sr. No.	Category	No of Applications received	No. of Equity Shares applied	No. of Equity Shares available for allocation (as per Prospectus)	No. of times Subscribed	Amount (₹)
A	Retail Individual Bidders	21,36,888	2,82,55,326	18,73,050	15.0852	37,55,18,27,522.00
B	Non-Institutional Bidders - More than ₹0.20 million Up to ₹1.00 million	1,17,358	1,88,05,644	9,36,525	20.0802	24,99,30,27,928.00
C	Non-Institutional Bidders - Above ₹1.00 million	58,961	4,69,98,402	18,73,051	25.0919	62,46,06,38,702.00
D	Eligible Employees	5,948	1,41,911	65,000	2.1832	18,85,39,021.00
E	Qualified Institutional Bidders (excluding Anchor Investors)	184	45,28,83,409	56,19,154	80.5964	6,01,88,20,50,561.00
	TOTAL	**23,19,339**	**54,70,84,692**	**1,03,66,780**	**52.77**	**7,27,07,60,83,734.00**

Final Demand

A summary of the final demand as per BSE and NSE as on the Bid/ Offer Closing Date at different Bid prices is as under:

Sr. No.	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % to Total
1	1265	58,674	0.01	58,674	0.01
2	1266	1,375	0.00	60,049	0.01
3	1267	583	0.00	60,632	0.01
4	1268	308	0.00	60,940	0.01
5	1269	2,365	0.00	63,305	0.01
6	1270	6,600	0.00	69,905	0.01
7	1271	209	0.00	70,114	0.01
8	1272	198	0.00	70,312	0.01
9	1273	209	0.00	70,521	0.01
10	1274	297	0.00	70,818	0.01
11	1275	2,453	0.00	73,271	0.01
12	1276	22	0.00	73,293	0.01
13	1277	143	0.00	73,436	0.01
14	1278	363	0.00	73,799	0.01
15	1279	638	0.00	74,437	0.01
16	1280	4,510	0.00	78,947	0.01
17	1281	110	0.00	79,057	0.01
18	1282	22	0.00	79,079	0.01
19	1283	77	0.00	79,156	0.01
20	1284	495	0.00	79,651	0.01
21	1285	495	0.00	80,146	0.01
22	1286	44	0.00	80,190	0.01
23	1287	187	0.00	80,377	0.01
24	1288	154	0.00	80,531	0.01
25	1289	968	0.00	81,499	0.01
26	1290	4,642	0.00	86,141	0.02
27	1291	55	0.00	86,196	0.02
28	1292	22	0.00	86,218	0.02
29	1293	66	0.00	86,284	0.02
30	1294	33	0.00	86,317	0.02
31	1295	1,034	0.00	87,351	0.02
32	1296	242	0.00	87,593	0.02
33	1297	1,881	0.00	89,474	0.02
34	1298	1,199	0.00	90,673	0.02
35	1299	2,090	0.00	92,763	0.02
36	1300	22,550	0.00	1,15,313	0.02
37	1301	1,265	0.00	1,16,578	0.02
38	1302	297	0.00	1,16,875	0.02
39	1303	209	0.00	1,17,084	0.02
40	1304	33	0.00	1,17,117	0.02
41	1305	1,177	0.00	1,18,294	0.02
42	1306	55	0.00	1,18,349	0.02
43	1307	231	0.00	1,18,580	0.02
44	1308	33	0.00	1,18,613	0.02
45	1309	451	0.00	1,19,064	0.02
46	1310	3,201	0.00	1,22,265	0.02
47	1311	363	0.00	1,22,628	0.02
48	1312	44	0.00	1,22,672	0.02
49	1313	363	0.00	1,23,035	0.02
50	1314	220	0.00	1,23,255	0.02
51	1315	1,199	0.00	1,24,454	0.02
52	1317	88	0.00	1,24,542	0.02
53	1318	66	0.00	1,24,608	0.02
54	1319	968	0.00	1,25,576	0.02
55	1320	6,061	0.00	1,31,637	0.02
56	1321	704	0.00	1,32,341	0.02
57	1322	55	0.00	1,32,396	0.02
58	1323	1,474	0.00	1,33,870	0.02
59	1324	1,122	0.00	1,34,992	0.02
60	1325	6,336	0.00	1,41,328	0.03
61	1326	3,982	0.00	1,45,310	0.03
62	1327	24,244	0.00	1,69,554	0.03
63	1328	35,178	0.01	2,04,732	0.04
64	1329	52,47,59,807	94.78	52,49,64,539	94.81
65	CUT-OFF	2,87,17,051	5.19	55,36,81,590	100.00
	TOTAL	**55,36,81,590**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on December 17, 2024.

A. Allotment to Retail Individual Bidders (after rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at the Cut-Off Price or at the Offer Price of ₹1,329 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 14.62 times. The total number of Equity Shares Allotted in Retail Portion is 18,76,081 Equity Shares* to 1,70,552 successful Retail Individual Bidders. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	11	19,41,902	93.59	2,13,60,922	77.87	11	6:73	17,55,754
2	22	63,628	3.07	13,99,816	5.10	11	6:73	57,530
3	33	22,785	1.10	7,51,905	2.74	11	6:73	20,603
4	44	9,958	0.48	4,38,152	1.60	11	6:73	8,998
5	55	9,560	0.46	5,25,800	1.92	11	6:73	8,646
6	66	3,681	0.18	2,42,946	0.89	11	6:73	3,322
7	77	5,079	0.24	3,91,083	1.43	11	6:73	4,587
8	88	2,054	0.10	1,80,752	0.66	11	6:73	1,859
9	99	1,521	0.07	1,50,579	0.55	11	6:73	1,375
10	110	3,152	0.15	3,46,720	1.26	11	6:73	2,849
11	121	871	0.04	1,05,391	0.38	11	6:73	792
12	132	558	0.03	73,656	0.27	11	6:73	506
13	143	10,234	0.49	14,63,462	5.34	11	6:73	9,251
14	0	10938 Allottees from Serial no 2 to 13 Additional 1(one) share				1	9:10938	9
	TOTAL	**20,74,983**	**100.00**	**2,74,31,184**	**100.00**			**18,76,081**

**This includes spillover of 3,031 Equity Shares from Employee category.*

B. Allotment to Non-Institutional Bidders (more than ₹0.20 million and up to ₹1.00 million) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹0.20 million up to ₹1.00 million), who have bid at the Offer Price of ₹ 1,329 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 19.70 times. The total number of Equity Shares allotted in this category is 9,38,040 Equity Shares* to 3,031 successful applicants. The category-wise details of the Basis of Allotment are as under: (**Sample**)

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	154	109441	94.86	1,68,53,914	91.20	154	17:322	8,89,812
2	165	1956	1.70	3,22,740	1.75	154	1:19	15,862
3	176	393	0.34	69,168	0.37	154	21:393	3,234
4	187	261	0.23	48,807	0.26	154	14:261	2,156
5	198	213	0.18	42,174	0.23	154	11:213	1,694
11	264	47	0.04	12,408	0.07	154	2:47	308
12	275	61	0.05	16,775	0.09	154	3:61	462
13	286	29	0.03	8,294	0.04	154	2:29	308
14	297	88	0.08	26,136	0.14	154	5:88	770
15	308	317	0.27	97,636	0.53	154	17:317	2,618
20	363	48	0.04	17,424	0.09	154	3:48	462
21	374	518	0.45	1,93,732	1.05	154	27:518	4,158
22	385	118	0.10	45,430	0.25	154	6:118	92
36	616	24	0.02	14,784	0.08	154	1:24	154
39	737	18	0.02	13,266	0.07	154	1:18	154
40	748	211	0.18	1,57,828	0.85	154	11:211	1,694
513	693	8	0.01	5,544	0.03	154	0:8	0
514	704	1	0.00	704	0.00	154	0:1	0
515	726	8	0.01	5,808	0.03	154	0:8	0
516	0	All applicants from Serial no 501 to 515 for 1 (one) lot of 154 shares				154	2:91	308
517	0	313 Allottees from Serial no 2 to 516 Additional 1(one) share				1	26:313	26
	TOTAL	**1,15,367**	**100.00**	**1,84,80,066**	**100.00**			**9,38,040**

**This includes spillover of 1,515 Equity Shares from Employee category.*

C. Allotment to Non-Institutional Bidders (more than ₹1.00 million) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹1.00 million), who have bid at the Offer Price of ₹1,329 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 24.79 times. The total number of Equity Shares allotted in this category is 18,76,083 Equity Shares* to 12,182 successful applicants. The category-wise details of the Basis of Allotment are as under: (**Sample**)

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	759	56033	95.99	4,25,29,047	91.44	154	24:115	18,00,876
2	770	894	1.53	6,88,380	1.48	154	9:43	28,798
3	781	217	0.37	1,69,477	0.36	154	45:217	6,930
4	792	103	0.18	81,576	0.18	154	21:103	3,234
5	803	90	0.15	72,270	0.16	154	19:90	2,926
6	814	51	0.09	41,514	0.09	154	11:51	1,694
7	825	78	0.13	64,350	0.14	154	16:78	2,464
8	836	78	0.13	65,208	0.14	154	16:78	2,464
1016	1,562	1	0.00	1,562	0.00	154	0:1	0
1017	1,584	2	0.00	3,168	0.01	154	0:2	0
1018	1,672	1	0.00	1,672	0.00	154	0:1	0
1019	1,705	1	0.00	1,705	0.00	154	0:1	0
1020	1,760	2	0.00	3,520	0.01	154	0:2	0
1021	1,793	1	0.00	1,793	0.00	154	0:1	0
1022	1,804	1	0.00	1,804	0.00	154	0:1	0
1023	1,815	2	0.00	3,630	0.01	154	0:2	0
1024	1,826	1	0.00	1,826	0.00	154	0:1	0
1025	1,837	1	0.00	1,837	0.00	154	0:1	0
1138	67,716	1	0.00	67,716	0.15	154	0:1	0
1139	75,240	1	0.00	75,240	0.16	154	0:1	0
1140	86,526	1	0.00	86,526	0.19	154	0:1	0
1141	2,37,336	1	0.00	2,37,336	0.51	154	0:1	0
1142	3,76,233	1	0.00	3,76,233	0.81	154	0:1	0
1143	0	All applicants from Serial no 1001 to 1142 for 1 (one) lot of 154 shares				154	33:175	5,082
1144	0	12182 Allottees from Serial no 1 to 1143 Additional 1(one) share				1	55:12182	55
	TOTAL	**58,373**	**100.00**	**4,65,08,462**	**100.00**			**18,76,083**

**This includes spillover of 3,032 Equity Shares from Employee category.*

D. Allotment to Employee Reservation (after rejections) (including ASBA Applications)

The Basis of Allotment to the Eligible Employee Portion, who have bid at the Offer Price of ₹ 1,329 per Equity Share was finalized in consultation with the NSE. This category has been subscribed to the extent of 0.53 times. The total number of Equity Shares allotted in this category is 34,683 Equity Shares to 665 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	11	364	54.74	4,004	11.54	11	1:1	4,004
2	22	104	15.64	2,288	6.60	22	1:1	2,288
3	33	37	5.56	1,221	3.52	33	1:1	1,221
4	44	22	3.31	968	2.79	44	1:1	968
5	55	13	1.95	715	2.06	55	1:1	715
6	66	8	1.20	528	1.52	66	1:1	528
7	77	18	2.71	1,386	4.00	77	1:1	1,386
8	88	1	0.15	88	0.25	88	1:1	88
9	99	5	0.75	495	1.43	99	1:1	495
10	110	10	1.50	1,100	3.17	110	1:1	1,100
11	121	4	0.60	484	1.40	121	1:1	484
12	132	4	0.60	528	1.52	132	1:1	528
13	143	8	1.20	1,144	3.30	143	1:1	1,144
14	154	8	1.20	1,232	3.55	154	1:1	1,232
15	165	3	0.45	495	1.43	165	1:1	495
16	176	1	0.15	176	0.51	176	1:1	176
17	187	1	0.15	187	0.54	187	1:1	187
18	198	3	0.45	594	1.71	198	1:1	594
19	209	2	0.30	418	1.21	209	1:1	418
20	220	3	0.45	660	1.90	220	1:1	660
21	231	4	0.60	924	2.66	231	1:1	924
22	264	1	0.15	264	0.76	264	1:1	264
23	275	1	0.15	275	0.79	275	1:1	275
24	286	1	0.15	286	0.82	286	1:1	286
25	297	2	0.30	594	1.71	297	1:1	594
26	308	2	0.30	616	1.78	308	1:1	616
27	330	1	0.15	330	0.95	330	1:1	330
28	363	3	0.45	1,089	3.14	363	1:1	1,089
29	374	31	4.66	11,594	33.43	374	1:1	11,594
	TOTAL	**665**	**100.00**	**34,683**	**100.00**			**34,683**

***Note**: 30,317 of Equity shares are spilled over from Employee category to QIB, Non Institutional & Retail Category due to undersubscription in employee category.*

E. Allotment to QIBs (Excluding Anchor Investors) (after rejections)

Allotment to QIBs, who have Bid at the Offer Price of ₹ 1,329 per Equity Share, has been done on a proportionate basis in consultation with the NSE. This category has been subscribed to the extent of 80.60 times of QIB Portion. As per the SEBI Regulations, Mutual Funds were Allotted 5% of the Equity Shares of QIB Portion available i.e., 2,82,095 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e., 53,59,798 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 56,41,893 Equity Shares* which were allotted to 184 successful QIB Investors. The category-wise details of the Basis of Allotment are as under:

Category	FIs/BANKs	MF's	IC's	NBFC's	AIF	FPC	VC's	TOTAL
QIBs	19,23,052	5,12,793	2,84,636	4,60,212	2,37,548	22,23,652	-	**56,41,893**

**This includes spillover of 22,739 Equity Shares from Employee category.*

F. Allotment to Anchor Investors

The Company, in consultation with the BRLMs, have allocated 84,28,730 Equity Shares to 47 Anchor Investors (through 61 Applications) at the Anchor Investor Offer Price of ₹ 1,329 per Equity Share in accordance with the SEBI Regulations. This represents 60% of the QIB Portion.

Category	FIs/BANKs	MF's	IC's	NBFC's	AIF	FPC	Others	TOTAL
Anchor	-	28,09,577	3,89,251	86,467	3,68,698	47,74,737	-	**84,28,730**

The IPO Committee of our Company on December 17, 2024 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being the NSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Intimations and/or notices have been dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Issue Account have been issued on December 17, 2024 and payment to non-Syndicate brokers have been issued on December 18, 2024. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on December 18, 2024 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the listing application with BSE and NSE on December 18, 2024. The Company has received listing and trading approval from BSE and NSE, and the trading will commence on Thursday, December 19, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS PLEASE NOTE

These details of the Allotment made was hosted on the website of the Registrar to the Offer, Link Intime India Private Limited at www.linkintime.co.in

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

LINK Intime

Link Intime India Private Limited
C-101, 1st Floor, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083, Maharashtra, India
Tel: +91 810 811 4949; **E-mail**: ikshealth.ipo@linkintime.co.in
Website: www.linkintime.co.in; **Investor grievance e-mail:** ikshealth.ipo@linkintime.co.in
Contact person: Shanti Gopalkrishnan; **SEBI Registration No.:** INR000004058

For **INVENTURUS KNOWLEDGE SOLUTIONS LIMITED**
On behalf of the Board of Directors
Sd/-
Sameer Chavan
Company Secretary and Compliance Officer

Place: Navi Mumbai
Date: December 18, 2024

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF INVENTURUS KNOWLEDGE SOLUTIONS LIMITED.

INVENTURUS KNOWLEDGE SOLUTIONS LIMITED has filed the Prospectus dated December 16, 2024 with RoC. The Prospectus is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at https://www.ikshealth.com and on the websites of the BRLMs, i.e. ICICI Securities Limited, Jefferies India Private Limited, JM Financial Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.icicisecurities.com, www. jefferies.com, www.jmfl.com, www.jpmipl.com and http://www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see '*Risk Factors*' on page 31 of the Prospectus. Potential investors should not rely on the DRHP for making any investment decision but should only rely on the information included in the Prospectus filed by the Company with the RoC.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**") or any state securities law in the United States and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. Accordingly, the Equity Shares are being offered and sold (a) within the United States solely to persons who are reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (b) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and pursuant to the applicable laws of the jurisdiction where those offers and sales are made.